Prioritizing kids first is core to our mission, and our pipeline reflects that.

We believe our portfolio of technology has the potential to make a significant impact in how pediatric brain tumors are treated, as well as expand to other types of CNS tumors in adults, including glioblastoma and brain metastases.

Clinical Update BCB-276

BrainChild Bio will proceed directly to a single pivotal registrational trial, designed to accelerate the path to submit a Biologics License Application (BLA) for the treatment of children and young adults with DIPG. This clinical plan is based on alignment at a Type B meeting with the U.S. Food and Drug Administration (FDA).

Expanded Access Policy

BrainChild Bio is committed to developing advanced cellular therapies for people of all ages with tumors of the central nervous system.

Our goal is to develop new treatment options responsibly and thoughtfully. We believe that clinical trials are the most appropriate way to understand the safety and effectiveness of our therapies and work toward making them broadly available to those who may benefit from them.

Expanded access, sometimes referred to as compassionate use, is a regulatory pathway that allows people to seek access to investigational products outside of a clinical trial.

At this time, access to our investigational products is available only through participation in clinical trials. BrainChild Bio does not provide any investigational products through expanded access or compassionate use programs.

Information about our clinical trial can be found at https://clinicaltrials.gov/study/NCT07680439.